A combination of cisplatin, methotrexate, bleomycin, and vincristine (CABO) was assessed in advanced epidermoid head and neck cancer. Among 72 patients with recurrent or metastatic disease and measurable lesions, there were 9 complete and 27 partial responses for an overall response rate of 50%. The
Combined chemotherapy of head and neck squamous cell carcinomas with methotrexate, bleomycin, and hydroxyurea
β Scribed by R. Medenica; P. Alberto; W. Lehmann
- Book ID
- 112286095
- Publisher
- Springer
- Year
- 1981
- Tongue
- English
- Weight
- 412 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## For the EORTC Head and Neck Cooperative Group A total of 185 eligible patients with advanced inoperable squamous cell carcinoma of the head and neck were randomized into two groups; the cisplatin, methotrexate, bleomycin, and vincristine (CABO) group received cisplatin (50 mg/m2; day 4), methot
## Abstract A combination of cyclophosphamide, adriamycin, methotrexate, and bleomycin (CAMB) was explored in patients with advanced, nonresectable epidermoid carcinoma from primary sites in the head and neck, recurrent or persistent after radiation or surgery. Objective regression (greater than 50
## Abstract Fortyβthree patients with Stage III or IV squamous cell carcinoma of the head and neck were treated with simultaneous hydroxyurea and bleomycin in four treatment levels and with fullβdose radiotherapy. Complete responses ranged from 28 to 50% (P = .47), and complete plus partial respons